Financial News Feed

Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on July 11) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Novocure Ltd (NASDAQ: NVCR ) Penumbra Inc (NYSE: PEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 11) Aimmune Therapeutics Inc (NASDAQ: AIMT )(fell on a release from the Institute for Clinical and Economic Review, which expressed skepticism about peanut allergy drug vis-à-vis avoiding the food altogether) Amneal Pharmaceuticals Inc (NYSE: AMRX ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Iradimed Corp (NASDAQ: IRMD ) See Also: Attention Biotech Investors: Mark Your Calendar For These … Full story available on Benzinga.com

Read more

Aimmune Therapeutics (AIMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read more

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q1 2019 Earnings Conference Call May 08, 2019 4:30 PM ET Company Participants Eric Bjerkholt - Chief Financial Officer

Read more

AIMT earnings call for the period ending March 31, 2019.

Read more

Aimmune Therapeutics beats by $0.10
08:06pm, Wednesday, 08'th May 2019

Read more

Aimmune Therapeutics Q1 Earnings Preview
09:35pm, Tuesday, 07'th May 2019
Aimmune Therapeutics (NASDAQ:AIMT) is scheduled to announce Q1 earnings results on Tuesday, May 7th, after market close. The consensus EPS Estimate is -$0.

Read more

Here we will take a look into some valuation metrics for Aimmune Therapeutics, Inc. NasdaqGS:AIMT shares. Price-To-Cash-Flow-Ratio is a term that indicates the degree of cash flow valuation of the ent

Read more

Both Neurotrope Inc. (NASDAQ:NTRP) and Aimmune Therapeutics Inc. (NASDAQ:AIMT) are each other’s competitor in the Biotechnology industry. Thus the compare of their profitability, analyst recommendat

Read more

This is a contrast between Akcea Therapeutics Inc. (NASDAQ:AKCA) and Aimmune Therapeutics Inc. (NASDAQ:AIMT) based on their risk, analyst recommendations, profitability, dividends, institutional owner

Read more

MorphoSys AG (NASDAQ:MOR) and Aimmune Therapeutics Inc. (NASDAQ:AIMT), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst

Read more

Proudly made at

ROCKIT